Pituitary tumor disappearance in a patient with newly diagnosed acromegaly primarily treated with octreotide LAR.

Department of Endocrinological and Metabolic Sciences, University of Genoa, Genoa, Italy.
Journal of endocrinological investigation (Impact Factor: 1.55). 03/2005; 28(2):166-9. DOI: 10.1007/BF03345361
Source: PubMed

ABSTRACT We describe the case of an acromegalic patient primarily treated with octreotide LAR in whom the pituitary tumor disappeared after 18 months of treatment. A 68-yr-old woman, with clinical suspicion of acromegaly, was admitted to our Unit with the ultrasonographical evidence of cardiac hypertrophy, arrhythmias, right branch block and interatrial septum aneurism. She referred hands and feet enlargement since the age of 30 and facial disfigurements since the age of 50. At the age of 45 she underwent surgery for carpal tunnel syndrome and at the age of 61 an euthyroid nodular goiter was diagnosed. Hormonal evaluation showed elevated circulating GH levels (25+/-3.2 ng/ml), not suppressible after oral glucose load, and elevated IGF-I levels (646 ng/ml), whereas the remaining pituitary function was normal. Visual perimetry was normal, whereas magnetic resonance imaging (MRI) showed an intrasellar pituitary adenoma with maximal diameter of 9 mm. In order to improve cardiovascular function before surgery, the patient started octreotide LAR 20 mg every 4 weeks for 3 months. Then based on IGF-I values, the dose was adjusted to 30 mg. After 6 months a second MRI showed significant tumor reduction (>50% of baseline maximal diameter), GH and IGF-I were within the normal range and the patient continued the treatment. After one-year therapy, an improvement of cardiac alterations was recorded and the patient was referred to the neurosurgeon. However, she refused the operation. At 18-month follow-up, MRI showed the complete disappearance of direct and indirect signs of pituitary adenoma. To our knowledge, this is the first case of complete radiological remission of pituitary tumor during octreotide LAR treatment in acromegaly.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Acromegaly is an insidious and uncommon disorder caused by chronic growth hormone hypersecretion. Transsphenoidal surgery is the treatment of choice in most patients with acromegaly. However, primary medical treatment with somatostatin analogs can be offered to patients with macroadenomas that cannot be completely resected and do not cause compression symptoms. Several studies have shown that primary medical therapy with somatostatin analogs controls growth hormone and insulin-like growth factor-I levels and decreases tumor volume in a significant percentage of patients. We report the case of a patient with acromegaly who received primary medical treatment with a somatostatin analog without response. The treatment was changed to lanreotide autogel, producing disappearance of the pituitary adenoma.
    Endocrinología y Nutrición 10/2007; 54(8). DOI:10.1016/S1575-0922(07)71483-3
  • [Show abstract] [Hide abstract]
    ABSTRACT: Acromegaly is a rare and potentially life-threatening disease in adults related to excessive production of growth hormone (GH) by pituitary gland tumors and characterized by progressive somatic disfigurement that is associated with systemic manifestations related to organ overgrowth. Somatostatin analogs (SSAs) are effective in controlling GH/IGF-1 hypersecretion and in reducing tumor size. We review and compare the pharmacokinetic and clinical efficacy of lanreotide, the second SSA available in the market, in its different formulations. This article concisely reviews the rationale of SSA treatment in acromegaly and the pharmacology and clinical efficacy of lanreotide and provides a detailed overview of its pharmacokinetic profiles in its slow release (SR) and autogel (ATG) formulations. Lanreotide is an effective and well-tolerated drug for the treatment of acromegaly. Lanreotide ATG has a more favorable pharmacokinetic profile than lanreotide SR, which permits administration once every 28 - 56 days given deep subcutaneously and by self-injection rather than intramuscular injection every 7 - 14 days. In well-designed clinical trials, subcutaneous lanreotide ATG was shown to be no less effective than intramuscular lanreotide SR or octreotide treatment.
    Expert Opinion on Drug Metabolism &amp Toxicology 10/2010; 6(10):1301-12. DOI:10.1517/17425255.2010.513700 · 2.93 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Somatostatin analogs (SA) are the cornerstone in the medical treatment of acromegaly, used as either primary or adjunctive therapy. In particular, SA are effective in inducing the biochemical remission of the disease and tumor shrinkage, although only few cases of complete disappearance of the pituitary tumor in patients treated with SA as long-acting formulations have been reported. SA withdrawal has been demonstrated to keep safe levels of GH and IGF1 at least in a small subset of patients well responsive to SA, although it is generally followed by disease recurrence after several months. A 61-year-old female patient bearing a very large GH-secreting pituitary macroadenoma was treated with 12-month lanreotide Autogel (ATG), at the initial dose of 120 mg/28 days. After 3 months, GH and IGF1 levels were fully normalized, to prolong the administration interval from 28 to 56 days. After 6 months of treatment, a significant tumor shrinkage (90% of baseline size) was observed, whereas GH and IGF1 excess was still well controlled. After 12-month therapy, a complete disappearance of the pituitary tumor was observed, and the hormonal evaluation confirmed the complete biochemical remission of acromegaly. Lanreotide ATG treatment was withdrawn. The clinical, biochemical, and radiological remission of acromegaly was maintained 24 months after lanreotide ATG treatment discontinuation, without evidence of disease recurrence. This report represents an exemplary case of the potentiality of treatment with lanreotide ATG in inducing a complete remission of acromegalic disease, persistent after a long period of time from treatment withdrawal.
    European Journal of Endocrinology 02/2010; 162(5):993-9. DOI:10.1530/EJE-09-0769 · 3.69 Impact Factor